Dear Colleagues,
I hope you'll be able to join us for the 2018 FH Global Summit. We have a stellar agenda planned. For example, the session on
Cardiovascular Risk Stratification in the FH Population
focuses on the critically important issue of determining cardiovascular risk in FH using genetics, biomarkers, and imaging of plaque.
The lineup of speakers for this session is world class!
Catherine Boileau
and
Marianne Abifadel
discovered the relationship between PCSK9 and LDL cholesterol through their groundbreaking studies of FH families without LDL receptor mutations. Together, they will present on their fascinating work on modifier genes in FH.
Amy Sturm
from Geisinger led an FHF-convened global group of experts in rigorously assessing the data supporting genetic testing in FH, and will summarize this consensus document which is under consideration for publication.
Lp(a) is one of the most important biomarkers influencing CV risk in FH.
Anne Tybjærg-Hansen
from Copenhagen is a world leader in studies of Lp(a), its genetics, and its relationship to CV risk. She will provide an update on Lp(a) in FH.
Finally, there have been major advances in technology for non-invasive imaging atherosclerotic plaque, and evidence that such imaging can improve CV risk stratification.
Zahi Fayad
, from Mt. Sinai in New York, is the world’s leading investigator in plaque imaging. We are delighted that he will join the Summit faculty and cap off this session by providing a state-of-the-art update on plaque imaging and its relevance to FH.
We look forward to you
joining us
for another amazing FH Global Summit!
